Accelovance

Accelovance

Accelovance

  • Jan 31 at 4:32 PM
    Looking to enhance your trial's patient recruitment and retention? Accelovance's Patient Engagement Solutions is your answer. Our robust clinical call center provides clients with a full-suite of services to improve enrollment and compliance on programs of all magnitudes. Discover more https://hubs.ly/H09FPDW0
  • Jan 24 at 2:00 PM
    Scientists are taking a cue from bioluminescent marine animals to help identify which cancer immunotherapies are working. CAR-T cells are a promising area in cancer research, but thus far the method for determining effectiveness (the radioactive chorimium release assay) has been costly and complex. A new assay, using the animal luciferases enzyme found in deep sea crustaceans and shrimp, is proving to be powerful, inexpensive and fast at detecting cancer cell death. This is an exciting discovery for cancer immunotherapy. Read more https://hubs.ly/H09FSRH0
  • Jan 18 at 3:15 PM
    Do you have a promising immuo-oncology therapy in development? Turn to Accelovance for results. Accelovance specializes in oncology clinical development, with a strong focus in IO programs including immune checkpoint modulators, cellular immunotherapies, oncolytic viruses, peptide vaccines, bispecific T-cell engagers, and tumor vaccines. Set up a meeting with our of our medical experts and learn more. https://hubs.ly/H09y1110
  • Jan 15 at 1:45 PM
    Accelovance is pleased to be kicking off a new trial for bladder cancer. Our early phase oncology team is ready to take on this program. Learn more about our HERO Initiative, helping early research in oncology. https://hubs.ly/H09x_pw0

Jan 31, 4:32 PM

Looking to enhance your trial's patient recruitment and retention? Accelovance's Patient Engagement Solutions is your answer. Our robust clinical call center provides clients with a full-suite of services to improve enrollment and compliance on programs of all magnitudes. Discover more https://hubs.ly/H09FPDW0

Jan 24, 2:00 PM

Scientists are taking a cue from bioluminescent marine animals to help identify which cancer immunotherapies are working. CAR-T cells are a promising area in cancer research, but thus far the method for determining effectiveness (the radioactive chorimium release assay) has been costly and complex. A new assay, using the animal luciferases enzyme found in deep sea crustaceans and shrimp, is proving to be powerful, inexpensive and fast at detecting cancer cell death. This is an exciting discovery for cancer immunotherapy. Read more https://hubs.ly/H09FSRH0

Jan 18, 3:15 PM

Do you have a promising immuo-oncology therapy in development? Turn to Accelovance for results. Accelovance specializes in oncology clinical development, with a strong focus in IO programs including immune checkpoint modulators, cellular immunotherapies, oncolytic viruses, peptide vaccines, bispecific T-cell engagers, and tumor vaccines. Set up a meeting with our of our medical experts and learn more. https://hubs.ly/H09y1110

Jan 15, 1:45 PM

Accelovance is pleased to be kicking off a new trial for bladder cancer. Our early phase oncology team is ready to take on this program. Learn more about our HERO Initiative, helping early research in oncology. https://hubs.ly/H09x_pw0

2 jobs at Accelovance

Jobs in